SGNSTNV-001 (Seagen, Inc.)
Description: A Phase 1 Study of SGN-STNV in Advanced Solid Tumors
Mechanism of Action: Antibody drug conjugate to STn, a tumor associated carbohydrate antigen conjugated with MMAE toxin (tubulin disrupting agent). Highly expressed in mucinous and serous cancers.
Target Patient Population: All solid tumors.
Study Design: Drug is administered IV Day 1, 8 and 15 of a 21 day cycle